好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Update on Experience with Natalizumab Use, JCV Antibody Testing & Treatment Decisions at the University of Southern California MS Center - Including Sex Differences
MS and Related Diseases
P01 - (-)
213
BACKGROUND: A positive antibody status indicates prior exposure to JC virus and a detectable immune response to an otherwise asymptomatic virus. Patients who are anti-JCV antibody positive are thought to have a higher risk for developing PML. The risks and benefits of continuing treatment with natalizumab are carefully considered in the context of other potential risk factors.
DESIGN/METHODS: Over 220 JCV Ab tests were done on over 175 unique patients at our center, noting greater than 120 patients were on natalizumab at the time of initial antibody testing, and more than 50 were not. We separated the patients based on sex, male or female, and categorized the testing and whether patients were subsequently treated with natalizumab.
RESULTS: At time of abstract submission, over 50% of patients were noted to test positive for JCV antibodies upon initial test and we saw a greater percentage of males than females test positive, while noting fewer were tested or treated with natalizumab.
CONCLUSIONS: How to utilize this test and how it may be most effectively used may be different for individual patients, potentially with regards to sex - we believe the presentation of this data and our interpretation of it may help others as they make complex treatment decisions.
Authors/Disclosures
Eric Williamson, MD (UCLA/West Los Angeles Veterans Admin Hospital)
PRESENTER 		Dr. Williamson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG therapeutics. Dr. Williamson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Williamson has received research support from Biogen. Dr. Williamson has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with Veterans administration.
Jose Aparicio No disclosure on file
No disclosure on file
Margaret E. Burnett, MD (University of Southern California, Keck School of Medicine) Dr. Burnett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prism. Dr. Burnett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD serono. Dr. Burnett has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Dr. Burnett has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Burnett has received research support from Genentech.
Krzysztof W. Selmaj (University of Warmia and Mazury) Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.